Chuangteng Technology Secures Tens of Millions of RMB in Series A Funding Led by Chengwei Capital, with Hyfinity as Exclusive Financial Advisor

VCBeat has learned that recently,Chuangteng Technology, the R&D intelligence engine for China’s process manufacturing industry, announced the completion of its Series A financing round, raising tens of millions of RMB. The round was led by Chengwei Capital, with Haoyue Capital serving as the exclusive financial advisor. The funds will accelerate Chuangteng Technology’s product development and team building, further expand its market presence, and deepen digital penetration across the industry.

Chuangteng Technology primarily serves the process manufacturing industry, focusing on R&D innovation and quality compliance in life sciences and materials science. It provides comprehensive digital solutions based on industry best practices and technologies such as big data and AI. Currently, Chuangteng Technology has built integrated solutions covering multiple scenarios and the entire R&D workflow, helping innovative enterprises and research institutions accelerate their digital transformation in R&D, achieve intelligent innovation, meet regulatory compliance requirements, and address critical bottlenecks currently facing the process manufacturing industry.

Chuangteng possesses profound scenario-based insights into the R&D processes of process manufacturing industries. By innovatively integrating cutting-edge technologies such as AI, big data, and cloud-native architectures, Chuangteng Technology has launched core products including the iLabPower Digital R&D Platform, the SDH Scientific Data Genome, and the MaXFlow Molecular Simulation and Artificial Intelligence Platform. Additionally, it provides integrated solutions spanning from digital R&D to intelligent innovation. From data acquisition and management to data extraction, integration, and business intelligence enablement, and further to AI model-based intelligent simulation software, Chuangteng Technology comprehensively empowers innovative enterprises and R&D institutions to build data-driven engines for intelligent innovation.

To date, Tri-Thera Technology has served over 1,200 clients, ranking among the industry leaders. In the field of life sciences, its partners include leading pharmaceutical companies such as WuXi AppTec, Hengrui Medicine, HEC Pharm, Nhwa Pharmaceutical, Qilu Pharmaceutical, and Guobang Pharma, as well as numerous emerging innovators in innovative drug R&D, including Yilian Biologics, Kintor Pharmaceutical, 3D Medicines, and Beiheng Biotechnology. In the field of materials science, its partners encompass large enterprises such as Sinopec, CNOOC, Shanghai Huayi Group, Juhua Group, and CATL, along with many innovative companies specializing in new materials for applications such as chip photoresists and 3D printing. Furthermore, nearly all 985 universities and research and teaching institutions under the Chinese Academy of Sciences (CAS) in the fields of life sciences and materials science maintain close and in-depth collaborations with Tri-Thera Technology.

The process manufacturing industry, represented by life sciences and materials science, suffers from a weak foundation in R&D informatization and still relies primarily on traditional paper-based methods, failing to meet the rapidly growing demand for R&D efficiency. Meanwhile, as regulatory authorities impose stricter oversight on R&D compliance and data integrity, the construction of informatization systems for R&D and production has become crucial for efficiently meeting regulatory compliance requirements. Currently, the overall penetration of informatization in the industry remains extremely low, with only a few leading enterprises having established relatively comprehensive informatization platforms. As the core momentum and driving engine for the future development of China’s life sciences and materials science sectors, the R&D segment urgently needs to undergo digital transformation and upgrading to accelerate R&D management efficiency and compliance standards. Furthermore, Chuangteng’s products can integrate, analyze, and deeply mine R&D data, leveraging technologies such as big data and artificial intelligence to usher the R&D, production, and compliance processes of the process manufacturing industry into a new era.

Over the past three decades, China’s process manufacturing software market has long been monopolized by European and American software giants such as Dassault and Ansys, with domestic solutions failing completely in some critical areas. The design of intelligent manufacturing software involves extremely high complexity and barriers to entry, requiring the accumulation and integration of extensive interdisciplinary industry know-how. Simulation analysis through such software can significantly reduce trial-and-error costs for industrial products. However, China is currently facing severe “chokehold” challenges; in recent years, many Chinese universities have been placed on export control lists by Western software vendors, making the demand for domestically produced software increasingly urgent.

Leveraging over two decades of industry expertise, Chuangteng Technology enables enterprises to achieve digital transformation through comprehensive digital solutions. By deploying an intelligent innovation software platform, the company addresses critical technological bottlenecks and facilitates domestic substitution. Guided by its mission to “enhance clients’ business value and core competitiveness by providing professional IT solutions and services,” Chuangteng Technology drives growth through innovation, deeply integrating technology and services into clients’ R&D processes to resolve key industry pain points.

Mr. Cao Lingxiao, Founder of Chuangteng Technologystated, “We are delighted that iTechWorks has secured investment from Chengwei Capital, a professional investment firm with deep industry expertise in enterprise services, industrial software, and life sciences. We firmly believe that digitalization and intelligence will bring about profound transformations to R&D innovation in process manufacturing, unlocking a future market opportunity valued at hundreds of billions of yuan. As the innovation capabilities and R&D expenditures of Chinese domestic enterprises continue to rise, iTechWorks will persist in leveraging innovative applications of cloud computing, mobile internet, and scientific AI technologies to help enterprises and research institutions accelerate their digital transformation in R&D, achieve intelligent innovation, and drive the industry’s rapid growth.”

Mr. Gu Xuan, Partner at Capital ManagementIt is stated that China’s life sciences and new materials industries are entering a period of rapid, innovation-driven growth, with R&D investment rapidly increasing to hundreds of billions of yuan annually. These are typical knowledge-intensive and capital-intensive sectors; however, digitalization remains significantly lagging in laboratories where top-tier talent is concentrated. With the widespread adoption of a new generation of R&D paradigms centered on data and AI, the digitalization and intelligent transformation of the entire R&D process are garnering increasing attention.Chemexpress Technology focuses on R&D digitalization within the life sciences and new materials industries, leveraging profound technological expertise and industry experience. The company is further expanding its reach across the broader process manufacturing sector. Its products integrate all stages of the R&D workflow—including data acquisition, management, integration, collaboration, analysis, application, and compliance—empowering frontline laboratory researchers with AI capabilities and earning high recognition from over a thousand clients.The success of overseas vendors such as BIOVIA, Benchling, and Dotmatics has already demonstrated the substantial value of digitalizing R&D scenarios. We believe that Chemexpress Technology rivals, and even surpasses, these international counterparts in terms of product philosophy, architectural design, and the application of cutting-edge technologies like AI. Moreover, its solutions are better suited to the localized scenarios and needs of China’s R&D landscape. We look forward to Chemexpress Technology delivering greater value empowerment to China’s life sciences, new materials, and broader process manufacturing industries, thereby fueling the ascent of Chinese R&D.

Mr. Liu Hao, Founder and CEO of Haoyue CapitalIt is stated that the wave of digitalization and intelligence is sweeping through R&D at Chinese pharmaceutical companies, gradually transforming the entire new drug development process. Chemexpress’s R&D information management platform has been widely adopted by well-known domestic pharmaceutical R&D enterprises. Its science data-driven intelligent R&D products are capable of replacing imported foreign alternatives. We believe that Chemexpress boasts substantial client accumulation and deep industry expertise, positioning it with the potential to become a leading provider of digital transformation services in China’s life sciences sector. We are confident that, bolstered by capital support, Chemexpress will accelerate its growth and continue to deliver high-value, comprehensive digital solutions to its customers.

For two decades, Creaton Technology has been dedicated to the R&D sectors of pharmaceuticals and materials science. By innovatively applying cloud computing, mobile internet, and scientific artificial intelligence technologies, the company helps enterprises and innovative research institutions rapidly achieve digital transformation in R&D and realize intelligent innovation. Creaton Technology offers industry-leading integrated mobile internet solutions that span from digital R&D to intelligent innovation, including the iLabPower Digital R&D Platform (covering R&D and quality control), the SDH Scientific Data Genome Platform, and the MaXFlow Scientific AI Innovation Platform.

Chuangteng Technology serves over 1,000 clients, supporting tens of thousands of China’s technological elites. Leading domestic research institutions, top-tier pharmaceutical companies and CRO/CDMOs, petrochemical enterprises, and star players in novel drug discovery are all leveraging Chuangteng Technology’s digital R&D and intelligent innovation platform to execute their core strategies for intelligent innovation.

Chengwei Capital, founded in 1999, is one of the earliest international venture capital firms to invest in domestic Chinese enterprises. Adhering to a distinctive investment philosophy of selective and high-conviction investments, with a focus on identifying and nurturing unicorn companies, it has established China’s first evergreen fund, characterized by substantial capital resources and perpetual duration.

Over the past two decades, Chengwei Capital has invested in sectors including high-end manufacturing, internet, semiconductors, enterprise services, and digital health, with cumulative total investments exceeding USD 2 billion. Chengwei Capital has invested in more than 150 technology companies in China, 16 of which have successfully gone public, such as Sunny Optical, AAC Technologies, Sungrow Power Supply, Hanting Hotel, Youku, China Renaissance, AInnovation, and Roivant Sciences. The current investment portfolio also includes unicorn companies such as Hello TransTech, WM Motor, Baibu, XAG, Sila Nanotechnologies, StarFive, New Vision Medical, and Neopulse Medical.

Haoyue Capital, established in January 2014, is a leading industry-focused investment bank in China specializing in the healthcare sector. Headquartered in Shanghai, the firm maintains regional offices in Beijing and Shenzhen. Committed to empowering clients through capital and research-driven insights, Haoyue Capital facilitates the successful connection of outstanding Chinese healthcare enterprises with capital markets, thereby creating value-added benefits for its clients. The partnership team comprises senior investment bankers with extensive experience in China’s healthcare sector, supported by a professional team of over 70 members. Haoyue Capital closely monitors dynamics and trends in the healthcare investment market, with its research and transaction coverage spanning multiple sub-sectors, including biopharmaceuticals, innovative medical devices, IVD and life sciences, health services, and smart healthcare. In 2021, the firm completed more than 50 complex transactions involving private equity financing, mergers and acquisitions, and spin-offs of listed companies, with a total transaction value amounting to tens of billions of RMB, securing a leading position across various healthcare sub-sectors.